Invokana Adds Warnings On Amputation Risk, But Will It Give Jardiance An Edge?
Executive Summary
New data from J&J's cardiovascular outcomes trials shows leg and foot amputations occurred about twice as often in diabetes patients treated with canagliflozin versus placebo.
You may also be interested in...
Keeping Track: Flexion's Non-Opioid Knee Pain Drug Gets OK, Botox Gets Another Approval
The latest drug development news and highlights from our Performance Tracker.
CANVAS Trial Results: Better For Janssen, Lilly Or the SGLT2 Class?
Janssen's Invokana reduced cardiovascular events in CANVAS on par with the MACE reduction in Lilly's and Boehringer's EMPA-REG trial for competing SGLT2 inhibitor Jardiance, but the CV benefit comes with a doubling of amputation risk versus placebo.
J&J Plots Five-Year Pharma Growth Plan Around Mega-Brands And Launches
Management outlined how the company plans to achieve above-market compound-annual growth from 2016 to 2021 during an R&D Day near its New Jersey headquarters.